Integrated BioTherapeutics, a firm that specializes in
developing vaccines for infectious diseases and countermeasures for
bio-terrorism threats, is growing. The company recently moved into a new,
larger facility in the Gaithersburg Accelerator.
The move to a larger facility was spurred by the need for
more secure, dedicated lab space as the company develops new vaccine
technology. Integrated BioTherapeutics was recently awarded a grant from The
National Institute of Allergy and Infectious diseases to develop a second-generation
Ebola vaccine in partnership with the University of Texas Medical Branch. The company also received a grant from
NIAID in 2010 for research and development of a Staphylococcus vaccine. The
second phase of that research project is due to wrap up this year. Integrated
BioTherapeutics is currently working on projects to create vaccines for a host
of infectious diseases, including Dengue Fever, Staphylococcus, Streptococcus,
Marburg Viruses and Ebola.
"We have a drive to make something that changes the world,
to create a vaccine that mutes something that effects people. We strive to help
others do that too," says Rob Galioto, Director of Business Development at
Integrated BioTherapeutics.
Integrated Bio Therapeutics was recently honored at the
inaugural TEDCO ICE awards as Company of the Year.
The award was given in recognition of the company's growth.
Since its launch in 2008, Integrated BioTherapeutics has secured over $30
million in government research funding, and increased its staff size from one
employee to 30. The company is expecting to add five to ten staff positions in
the next year.
Author: Amy McNeal
Source: Rob Galioto, Integrated BioTherapeutics